Platinum-resistant Ovarian Cancer Clinical Trials

78 clinical trials for Platinum-resistant Ovarian Cancer across international registries, including 28 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China — RECRUITING · PHASE3
• A Study of MGC026 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. — RECRUITING · PHASE1
• A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. — RECRUITING · PHASE1
• Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) — RECRUITING · PHASE1
• A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) — RECRUITING · PHASE3
• A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer — RECRUITING · PHASE1
• A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer — RECRUITING · PHASE2
• GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer — RECRUITING · PHASE1
• Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer — RECRUITING · PHASE1
• A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of Lorigerlimab in Participants With Advanced Solid Tumors — RECRUITING · PHASE2
• IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer — RECRUITING · PHASE1
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha — RECRUITING · PHASE1
• A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer — RECRUITING · PHASE1
• A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer — RECRUITING · PHASE2
• A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SACITUZUMAB TIRUMOTECAN (MK-2870) MAINTENANCE TREATMENT WITH OR WITHOUT BEVACIZUMAB VERSUS STANDARD OF CARE AFTER SECOND-LINE PLATINUM-BASED DOUBLET CHEMOTHERAPY IN PARTICIPANTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (TROFUSE-022/ENGOT-OV84/GOG-3103) — RECRUITING · PHASE3
• MULTI-ARM PHASE 2 STUDY OF UBAMATAMAB (REGN4018; MUC16×CD3 BISPECIFIC ANTIBODY) WITH OR WITHOUT ADDITIONAL AGENTS IN PLATINUM-RESISTANT OVARIAN CANCER — RECRUITING · PHASE2
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) — RECRUITING · PHASE1
• A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF RINATABART SESUTECAN (RINA-S) VERSUS TREATMENT OF INVESTIGATOR'S CHOICE (IC) IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER — RECRUITING · PHASE3
• A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer — RECRUITING · PHASE2
• A MULTICENTER, OPEN-LABEL, PARALLEL, PHASE 2A STUDY OF PLX2853 MONOTHERAPY IN ADVANCED GYNECOLOGICAL MALIGNANCIES WITH A KNOWN ARID1A MUTATION AND PHASE 1B/2A STUDY OF PLX2853/CARBOPLATIN COMBINATION THERAPY IN PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER — RECRUITING · PHASE2
• PHASE 1 (SAFETY ASSESSMENT) OF DURVALUMAB (MEDI4736) WITH FOCAL SENSITIZING RADIOTHERAPY IN PLATINUM RESISTANT OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE EPITHELIAL CARCINOMA — RECRUITING · PHASE1
• A PHASE 1/2, OPEN-LABEL SAFETY AND EFFICACY EVALUATION OF CRS-207 IN COMBINATION WITH EPACADOSTAT IN ADULTS WITH PLATINUM-RESISTANT OVARIAN, FALLOPIAN, OR PERITONEAL CANCER — RECRUITING · PHASE1
• A PHASE 3, MULTI-CENTER, RANDOMIZED, OPEN-LABEL STUDY OF AVELUMAB (MSB0010718C) ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER — RECRUITING · PHASE3
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF RINA-S ± BEVACIZUMAB VERSUS INVESTIGATOR'S CHOICE OF PLATINUM-BASED CHEMOTHERAPY ± BEVACIZUMAB AS 2L TREATMENT IN PARTICIPANTS WITH RECURRENT PLATINUM-SENSITIVE OVARIAN CANCER — NOT_YET_RECRUITING · PHASE3
• A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers — NOT_YET_RECRUITING · PHASE3
• A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO INVESTIGATE MOCERTATUG REZETECAN WITH BEVACIZUMAB COMPARED WITH PLATINUM DOUBLET WITH BEVACIZUMAB IN PARTICIPANTS WITH PLATINUM-SENSITIVE OVARIAN CANCER — NOT_YET_RECRUITING · PHASE3
• A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. — NOT_YET_RECRUITING · PHASE1
• Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer — NOT_YET_RECRUITING · PHASE2
• Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. — ACTIVE_NOT_RECRUITING · PHASE1
• A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer — TERMINATED · PHASE1
• A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer — COMPLETED · PHASE1
• A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer — TERMINATED · PHASE3
• Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer — COMPLETED · PHASE1
• Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer — TERMINATED · PHASE1
• Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers — COMPLETED · PHASE1
• A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) — TERMINATED · PHASE2
• A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors — TERMINATED · PHASE1
• REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 — TERMINATED · PHASE2
• Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian — COMPLETED · PHASE2
• Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer — NOT_YET_RECRUITING · PHASE2
• Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) — TERMINATED · PHASE3

Refine this search